RPE65 and Leber congenital amaurosis: The Food and Drug Administration’s (FDA) landmark approval of voretigene neparvovec for RPE65-associated Leber Congenital Amaurosis (LCA) stimulated tremendous optimism regarding retinal gene therapy for other monogenic IRDs.